White, Michael A.

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 1,115

The exocyst is a Ral effector complex

Moskalenko, S., Henry, D. O., Rosse, C., Mirey, G., Camonis, J. H., & White, M. A. (2002) · Nature Cell Biology

Cellular transport and secretionProtein Kinase Regulation and GTPase Signaling

Cited by 423

XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer

Kim, J., McMillan, E., Kim, H. S., Venkateswaran, N., Makkar, G., Rodriguez-Canales, J., Villalobos, P., Neggers, J. E., Mendiratta, S., Wei, S., et al. (2016) · Nature

Nuclear Structure and FunctionLung Cancer Treatments and Mutations

Cited by 202

Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer

Kim, H. S., Mendiratta, S., Kim, J., Pecot, C. V., Larsen, J. E., Zubovych, I., Seo, B. Y., Kim, J., Eskiocak, B., Chung, H., et al. (2013) · Cell

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 172

Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer

McMillan, E. A., Ryu, M.-J., Diep, C. H., Mendiratta, S., Clemenceau, J. R., Vaden, R. M., Kim, J.-H., Motoyaji, T., Covington, K. R., Peyton, M., et al. (2018) · Cell

Computational Drug Discovery MethodsLung Cancer Treatments and Mutations

Cited by 141

Abstract 4710: Evaluation of the glutaminase inhibitor CB-839 in non-small cell lung cancer

Boroughs, L. K., Chen, P.-H., Cai, L., Rodriguez, M., Zhang, W., Huffman, K. E., Byers, L. A., Girard, L., Gazdar, A. F., Heymach, J. V., et al. (2015) · Cancer Research

Cancer, Hypoxia, and MetabolismAmino Acid Enzymes and Metabolism

Cited by 1